Operating Lease, Right-of-Use Asset of Theravance Biopharma, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Theravance Biopharma, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Theravance Biopharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $25,450,000, a 13% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Theravance Biopharma, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $25,450,000 -$3,884,000 -13% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $26,493,000 -$5,322,000 -17% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $27,430,000 -$7,934,000 -22% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $28,354,000 -$7,933,000 -22% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $29,334,000 -$8,242,000 -22% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $31,815,000 -$6,638,000 -17% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $35,364,000 -$3,840,000 -9.8% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $36,287,000 -$3,839,000 -9.6% 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $37,576,000 -$2,416,000 -6% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $38,453,000 -$2,659,000 -6.5% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $39,204,000 -$145,000 -0.37% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $40,126,000 +$436,000 +1.1% 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $39,992,000 -$726,000 -1.8% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $41,112,000 -$396,000 -0.95% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $39,349,000 -$3,168,000 -7.5% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $39,690,000 -$3,570,000 -8.3% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $40,718,000 -$3,673,000 -8.3% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 $41,508,000 -$3,676,000 -8.1% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $42,517,000 -$3,589,000 -7.8% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $43,260,000 -$3,344,000 -7.2% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $44,391,000 -$2,364,000 -5.1% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $45,184,000 -$2,647,000 -5.5% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $46,106,000 -$2,755,000 -5.6% 31 Mar 2020 10-Q 08 May 2020 2020 Q1
Q4 2019 $46,604,000 31 Dec 2019 10-K 26 Feb 2021 2020 FY
Q3 2019 $46,755,000 30 Sep 2019 10-Q 08 Nov 2019 2019 Q3
Q2 2019 $47,831,000 30 Jun 2019 10-Q 05 Aug 2019 2019 Q2
Q1 2019 $48,861,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.